Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a large decrease in short interest in the month of January. As of January 15th, there was short interest totaling 792,811 shares, a decrease of 22.3% from the December 31st total of 1,019,881 shares. Based on an average daily volume of 265,433 shares, the days-to-cover ratio is currently 3.0 days. Approximately 3.1% of the company’s stock are sold short. Approximately 3.1% of the company’s stock are sold short. Based on an average daily volume of 265,433 shares, the days-to-cover ratio is currently 3.0 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Armistice Capital LLC acquired a new stake in shares of Senti Biosciences during the second quarter worth about $1,883,000. Geode Capital Management LLC lifted its position in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares during the period. Finally, Citadel Advisors LLC purchased a new position in shares of Senti Biosciences in the 3rd quarter valued at approximately $117,000. 25.70% of the stock is owned by hedge funds and other institutional investors.

Senti Biosciences Stock Performance

Shares of SNTI stock opened at $1.00 on Monday. The stock’s 50-day moving average is $1.36 and its two-hundred day moving average is $1.58. Senti Biosciences has a 1 year low of $1.00 and a 1 year high of $5.10. The firm has a market cap of $26.29 million, a price-to-earnings ratio of -0.30 and a beta of 2.13.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). As a group, research analysts predict that Senti Biosciences will post -14.54 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on SNTI shares. HC Wainwright initiated coverage on Senti Biosciences in a research report on Tuesday, October 14th. They set a “buy” rating and a $12.00 price objective for the company. Leerink Partners began coverage on shares of Senti Biosciences in a report on Friday, November 21st. They set an “outperform” rating and a $6.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research report on Thursday, January 22nd. Chardan Capital boosted their target price on shares of Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Finally, Wall Street Zen upgraded Senti Biosciences to a “sell” rating in a research note on Saturday, December 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.